New technology acquisition provides Unither Pharmaceuticals with specialized transmucosal paracetamol solutions

Preliminary clinical trials have shown that this technology would enable to lower the dosage of paracetamol while keeping the same effect as traditional dosage for oral forms.

The deal comes after previous patents acquisitions by Unither Pharmaceuticals in the last years related to oro-dispersible formulations.

This addition will further enhance Unither Pharmaceuticals capabilities to deliver innovative solutions through its recently launched ODTechTM platform, offering several solid and liquid stick packs technologies.

Unither Pharmaceuticals’ CEO, Eric Goupil, said:

"This deal represents an important milestone for Unither Pharmaceuticals and its commitment to invest in R&D to facilitate patients’ daily life by developing affordable, convenient and easy to use products”

“It is also a significant addition to our ODTech platform, putting us in a very unique position with a multi-technology oral single dose strategy". 

Unither Pharmaceuticals’ Head of Innovation & Development, Nathalie Masson, commented:

"Our clients are looking for medicines with a shorter onset of action, especially when dealing with painkillers, to deliver great experiences to their customers.

This new technology will allow us to present a truly differentiated offering, enabling us to deliver innovative solutions to patients who want a faster acting painkiller. It will also support one of the firm's strategic priorities to further embed convenience into its products."

About Unither

Unither Pharmaceuticals was created in 1993 after the acquisition of Sanofi manufacturing plant in Amiens (France). Unither is a global contract development and manufacturing partner for proprietary and generic pharmaceutical dosage forms.

With a revenue of more than 260 million euros in 2017 and a workforce of more than 1,300 professionals, Unither Pharmaceuticals has 6 production sites in France, the United States and Brazil, a R&D center in France, as well as a sales subsidiary in China.

The group offers a wide range of products and is the world leader in the production of sterile single doses using Blow-Fill-Seal technology (forming, filling, sealing).